Abstract: A low vision aid system including a camera module to be used with a mobile device, including a macro camera configured to focus on near-field objects that is integrated within the low vision aid camera module and an illumination source structured to illuminate a field of view associated with the macro camera, a battery power supply and a wireless communication module. The wireless communication module establishes an isolated Wi-Fi connection to the mobile device. The isolated Wi-Fi connection prevents the mobile device from communicating over other Wi-Fi networks while the isolated Wi-Fi connection is maintained. The wireless communication module receives, via the isolated Wi-Fi connection, instructions from the mobile device, that are associated with operation of the macro camera, and sends via the isolated Wi-Fi connection, a video bitstream to the mobile device based on the instructions.

Abstract: The present invention relates to methods and compositions for the treatment of hematological malignancy by administering compositions comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug, e.g., sirolimus or a derivative thereof) and an albumin in combination with compositions comprising a second therapeutic agent.

Abstract: The present invention relates to methods and compositions for the treatment of hematological malignancy by administering compositions comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug, e.g., sirolimus or a derivative thereof) and an albumin in combination with compositions comprising a second therapeutic agent.

Abstract: The present invention relates to methods and compositions for the treatment of hematological malignancy by administering compositions comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug, e.g., sirolimus or a derivative thereof) and an albumin in combination with compositions comprising a second therapeutic agent.

Abstract: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that antagonizes a PD-1 pathway in a cell.